Glutathione Injections: Benefits, Dosage, Side Effects & Who Should Avoid Them

Key takeaways

• Glutathione is a tripeptide (glutamate, cysteine, glycine) that every cell makes for itself; it is the main antioxidant inside cells. The injections sold at clinics and by telehealth are compounded on prescription and are not FDA-approved.
• The human evidence is almost all oral. Small randomized trials found modest, reversible skin lightening with 250 to 500 mg a day by mouth. No published trial has tested intravenous or intramuscular glutathione for skin lightening, 'detox', energy or immunity, and the one IV skin study, in a non-indexed journal, was negative.
• Where IV glutathione has been tested properly it failed: a randomized pilot of 1,400 mg three times a week in Parkinson's disease found no benefit over placebo. The fatty-liver evidence is an uncontrolled pilot of oral glutathione in 29 patients.
• The clinic doses (600 to 1,200 mg IV one to three times a week) come from marketing, not trials. The Philippine FDA warned in 2011 and again in 2019 about Stevens-Johnson syndrome, kidney, thyroid and liver problems with IV whitening regimens at exactly those doses.
• Glutathione can be legally compounded in the US because FDA lists it in Category 1 of its 503A nominations, which lets pharmacies compound it while FDA evaluates it, but its safety record has one specific hole: endotoxin. FDA warned compounders in 2019 and again on August 27, 2026, after about 30 patients fell ill from IV glutathione made with dietary-supplement-grade powder; two pharmacies recalled lots and CDC opened an investigation. Ask where the powder came from before anyone injects it.

Glutathione at a glance

Also called

L-glutathione, reduced glutathione, GSH, glutathione peptide, gluta

Class

Endogenous tripeptide (glutamate, cysteine, glycine); the main antioxidant inside human cells; sold as compounded intravenous and intramuscular injections

Route

Intravenous push or infusion at clinics; intramuscular or subcutaneous injection from compounded multi-dose vials; also oral, sublingual, topical and nebulized forms

FDA status

No FDA-approved glutathione drug exists. Glutathione is in Category 1 of FDA's 503A nominations, which lets state-licensed 503A pharmacies compound it on prescription while FDA evaluates it; the compounded product is not FDA-reviewed for potency or sterility. FDA warned compounders in February 2019 and again on August 27, 2026 after endotoxin reactions to injections made from dietary-supplement-grade powder.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Yes, compounded on prescription by state-licensed pharmacies under FDA's interim Category 1 policy

Best-studied use

Oral glutathione for skin lightening (small randomized trials, 250 to 500 mg a day); intravenous glutathione in Parkinson's disease (randomized pilot, negative); oral glutathione in fatty liver (uncontrolled pilot). No published trial of intravenous or intramuscular glutathione for skin lightening, detox, energy or immunity.

Typical monthly cost (telehealth, 2026)

About $40 to $85 per intramuscular shot and $75 to $300 per IV session at clinics; at-home compounded vials by telehealth about $100 to $300 a month (price listings, October 2026)

What glutathione is and how it works

Glutathione is three amino acids, glutamate, cysteine and glycine, joined in an unusual way that makes it resistant to ordinary digestion. Every cell makes it, in millimolar amounts, and uses it for three jobs: donating electrons to neutralize reactive oxygen species, keeping the sulfur groups on proteins in their working state, and tagging drugs and toxins so the liver can excrete them. The cysteine is the working part and the scarce one; cells make glutathione as fast as they can get cysteine, which is why N-acetylcysteine, a cysteine source, has a longer and better trial record than glutathione itself for the conditions where raising glutathione matters.

That biology is the source of every claim on a glutathione menu, and of the main problem with the menu. Glutathione works inside cells, where it is made. In the bloodstream it is broken down by enzymes on cell surfaces and in the liver and kidneys into its amino acids, which cells then use to make their own. How much injected glutathione gets into cells intact, and whether a healthy person's cells, already full of it, do anything differently when it arrives, has not been shown (Sonthalia 2018). An IV push raises the blood level sharply for a short time; a shot does the same more slowly; what either does downstream is inferred, not measured.

The oral route has its own argument. Early single-dose studies found no rise in plasma glutathione after oral dosing, and are still quoted to say oral glutathione is useless. The better-designed answer came in 2015: in 54 adults randomized to 250 or 1,000 mg a day or placebo for 6 months, glutathione levels in blood, red cells and lymphocytes rose by 17 to 35 percent, returning to baseline a month after stopping (Richie 2015). Oral glutathione, taken for months, does raise body stores. Whether that is good for anything is the question the injection clinics skip.

What the evidence actually shows

Glutathione claims, graded by the human evidence behind them (route stated for each)

Claim	Grade	What the evidence shows	Sources
Oral glutathione lightens skin	B	In 60 Thai medical students randomized to 500 mg a day or placebo for 4 weeks, the melanin index fell at all six sites, significantly versus placebo at two. In a 12-week three-arm trial, 250 mg a day of reduced or oxidized glutathione tended to lower melanin index and reduced wrinkles at some sites. A 2025 systematic review counted five small randomized trials, with effects that faded after stopping.	Arjinpathana 2012; Weschawalit 2017; Sarkar 2025
Intravenous glutathione lightens skin	D	No trial in a PubMed-indexed journal. The one placebo-controlled study (16 per arm, Pakistani journal, 2016) found 6 versus 3 responders, not significant, with a design reviewers call flawed. The 2025 systematic review calls IV glutathione contraindicated for lack of efficacy and side effects; a 2016 South African review found no study of IV use for lightening or of long-term IV safety for any indication.	Sonthalia 2018; Sarkar 2025; Davids 2016
Glutathione helps Parkinson's disease	C	An open-label 1996 study of 600 mg IV twice daily for 30 days in 9 untreated patients reported a 42 percent improvement in disability. The randomized, double-blind follow-up (21 patients, 1,400 mg IV three times a week for 4 weeks) found no significant difference from placebo on UPDRS scores; it was well tolerated.	Sechi 1996; Hauser 2009
Glutathione treats fatty liver	C	An open-label pilot in 34 patients with NAFLD (29 completed) found that oral glutathione 300 mg a day for 4 months lowered ALT, triglycerides and ferritin after a 3-month lifestyle program. No control group, no injection data, and the authors call for a controlled trial.	Honda 2017
Glutathione injections detox the body, boost immunity or energy	D	No trial of injected glutathione has measured any of these. The closest data are oral: 6 months of 250 or 1,000 mg a day raised blood glutathione stores by 17 to 35 percent in 54 adults and doubled natural-killer-cell activity at 3 months, with no symptom or clinical outcome measured.	Richie 2015
Glutathione protects against cancer	D	Glutathione is what many tumors use to resist chemotherapy; raising it is a plausible way to make cancer treatment work less well, not better. No human prevention or treatment trial supports the marketing claim.	Traverso 2013
Short IV courses are well tolerated	C	In the Parkinson's trial and in chemotherapy-adjunct studies lasting a few doses to 12 weeks, adverse effects were minimal. No study has examined repeated weekly IV use for months or years.	Hauser 2009; Davids 2016
Compounded glutathione injections are safe as sold	D	Endotoxin-contaminated compounded glutathione caused 7 cases of probable endotoxin poisoning in Sydney (2018), 7 US patient reactions to one lot that prompted an FDA warning (2019), and about 30 adverse events with hospitalizations and two pharmacy recalls (2026). Nebulized glutathione caused bronchoconstriction in asthmatics, and Philippine regulators link IV whitening regimens to Stevens-Johnson syndrome and kidney and thyroid problems.	Johnstone 2018; FDA 2019; Pharma Now 2026; Marrades 1997; Dermatology Times 2011

Three things stand out.

The route with evidence is not the route being sold. Every randomized trial that found a skin effect used capsules or a lotion. The IV, the route clinics charge the most for, has one flawed negative study and a systematic review that calls it contraindicated (Sarkar 2025); a 2018 review by Indian dermatologists described the IV evidence as a single study with a dubious design and the oral and topical results as appreciable but reversible (Sonthalia 2018).

The one good IV trial was negative. Parkinson's disease has the best biological rationale for glutathione, because the affected brain region is depleted of it, and the open-label Italian study in 1996 looked striking (Sechi 1996). Tested blind against placebo at 1,400 mg three times a week, the groups did not differ (Hauser 2009). That is the pattern for most IV wellness claims: an uncontrolled study that excites people, then a controlled one that does not.

The safety story is about manufacturing, not pharmacology. Glutathione the molecule is unremarkable in short trials. Glutathione the compounded injectable has caused three documented clusters of endotoxin illness in eight years, each traced to the powder it was made from; that is the risk a buyer can do something about.

What you are promised versus what is documented

A typical clinic page lists detoxification, brighter and lighter skin, immune support, more energy, anti-aging, liver support, better athletic recovery and hangover relief. Sorted by evidence:

• Documented in humans (orally, modestly, reversibly): a lower melanin index after 4 to 12 weeks at 250 to 500 mg a day; higher body glutathione stores after months of daily dosing.
• Plausible but unproven: liver enzyme improvement in fatty liver (uncontrolled oral pilot); any effect of IV glutathione on anything, because the IV trials that exist are short, small and in diseases most buyers do not have.
• Not supported: 'detox' as a measurable outcome; immunity, energy, hangovers, athletic recovery, anti-aging; cancer prevention or treatment, where the biology runs the other way (Traverso 2013); any claim that the injection is stronger than the pill, which no study has tested.

Injection versus IV versus oral versus NAC

The two forms with the least evidence are the two that cost the most and carry the most risk. If someone wants to try glutathione for pigmentation, the studied version is a capsule, not a cannula; and for a clinician who actually wants to raise glutathione, NAC is the tool with a prescribing history.

Dosage: what was studied versus what clinics sell

Doses with published human data

Doses clinics and telehealth programs sell (marketing, not studied)

The gap runs the wrong way. The IV doses on offer are at or above the dose that failed in the one randomized IV trial, and the oral doses that worked, modestly, cost less than any session. There is no human evidence that injecting more does more than the pill did; there is evidence that it costs more and, in 2026, that it can hurt.

Volume example

Compounded glutathione injection is a solution, not a powder you reconstitute, so the arithmetic is volume. A typical vial is 200 mg/mL: 1 mL is 200 mg, 2 mL is 400 mg, and the 600 mg dose advertised for IM injection is 3 mL, more than a deltoid injection usually takes, which is why clinics split it or move to the IV. Our peptide calculator converts milligrams, milliliters and syringe units for any concentration, and our injection guide covers sites and technique; the pharmacy label overrides both.

Side effects and who should not use it

In the trials: very little. Oral glutathione for 4 weeks to 6 months and IV glutathione for 4 weeks were well tolerated, with adverse events similar to placebo (Hauser 2009). No trial has followed people on weekly IV glutathione for a year, so the long-term safety of what clinics sell is simply unknown (Davids 2016).

In practice, the harms come from the product and the setting.

• Endotoxin. Endotoxin is a residue of bacterial cell walls that survives sterilization and, injected, causes fever, chills, headache, vomiting, low blood pressure and, at high doses, shock and death. Glutathione powder sold as a dietary supplement is not made to the endotoxin limits required for injectable drugs, and compounded glutathione made from it has caused three documented clusters: seven cases of probable endotoxin poisoning from compounded infusions in Sydney, five in people using glutathione for Lyme disease (Johnstone 2018); seven US patients who reacted to IV glutathione from one supplier's lot, one needing hospital transfer, which led FDA to warn compounders on February 1, 2019 (FDA 2019) and to issue a broader alert about dietary-ingredient glutathione that June (FDA June 2019); and about 30 adverse events reported to FDA by August 27, 2026, with fever, chills, dizziness, pain and sepsis-like symptoms, hospitalizations, one supplier lot implicated and recalls by two Texas pharmacies (Pharma Now 2026), followed by a CDC investigation of more than 25 illnesses in four states (Healio 2026).
• Severe skin and organ reactions. The Philippine FDA, in the country where IV glutathione for whitening is most common, warned in May 2011 of Stevens-Johnson syndrome, toxic epidermal necrolysis, thyroid dysfunction, suspected kidney failure and severe abdominal pain in people receiving twice-weekly IV glutathione (Dermatology Times 2011), and repeated the warning in July 2019, adding liver, kidney and nervous-system toxicity, a theoretical skin-cancer concern and the infection risks of injections in non-medical settings, while noting that injectable glutathione is approved there only as an adjunct to cisplatin chemotherapy (GMA News 2019). These are case reports, not rates, and the regimens were 600 mg to 1.2 g once or twice weekly, the same ones US clinics sell.
• Asthma. Nebulized glutathione caused marked airway narrowing in a double-blind crossover study of eight people with mild asthma, an effect the investigators attributed to sulfite formed from the drug (Marrades 1997). That is the inhaled route, not IV, but it is the reason asthmatics should ask about sulfite preservatives in any compounded or multi-ingredient drip and should not accept an IV that cannot be stopped if they wheeze.
• Pigment and sun. The whitening effect, where it occurs, comes from shifting melanin production from brown eumelanin toward red pheomelanin; South African reviewers warn that doing this in previously protected skin may raise sun-induced skin cancer risk (Davids 2016).
• IV complications. Infection, phlebitis, infiltration and allergic reactions apply to any infusion, and med spas are not hospitals.

Do not use glutathione injections, or use them only with a specialist involved, if you:

• have asthma or a known sulfite sensitivity (see above);
• are pregnant or breastfeeding (no data for any injected regimen);
• have cancer or are receiving chemotherapy: glutathione is a mechanism of tumor chemoresistance (Traverso 2013), and any use alongside cancer treatment belongs to the oncologist, not a wellness menu. A clinic that claims glutathione prevents or treats cancer is making a claim no trial supports;
• have kidney or liver disease (the Philippine reports) or a history of severe drug reactions;
• are being offered a product whose pharmacy, ingredient grade and lot you cannot see.

Legal status in the United States

Glutathione is one of the few injectables on a peptide-clinic menu with a basis for compounding. There is no FDA-approved glutathione drug, and section 503A allows a state-licensed pharmacy to compound a bulk substance that has a USP or NF monograph, is a component of an approved drug, or appears on FDA's permitted list (FDA 503A). Glutathione's basis is FDA's interim policy instead: FDA lists it in Category 1 of its 503A nominations, which lets pharmacies compound it while FDA evaluates it (FDA categories 2026). A clinician can therefore prescribe it and a licensed pharmacy can fill it, which is why our legal tracker lists glutathione as compoundable alongside sermorelin and PT-141. FDA has never placed it in Category 2.

Compoundable is not the same as checked. FDA does not review a compounded product's potency, sterility or endotoxin content; the pharmacy and its state board are responsible, and the agency's two interventions in this market were about exactly that. In 2019, after the seven patient reactions, FDA warned compounders off the implicated lots and stated that glutathione sold as a dietary ingredient is not appropriate for sterile injectables (FDA June 2019). On August 27, 2026, with about 30 new reports, it said so again, told compounders that quality must be built in from ingredient sourcing onward and that end-product testing alone is not enough, and asked suppliers to state on certificates of analysis what uses an ingredient is suitable for (Pharma Now 2026). For a patient: the legal basis exists for now, under an interim policy that FDA could change when it finishes its evaluation, and the quality question is asked fresh with every vial.

State rules add a layer: telehealth prescribing requires a clinician licensed in your state, several states regulate which compounded products may be shipped in and who may administer an IV, and a med spa offering drips without a prescriber on the chart is on the wrong side of those rules whatever the product.

Cost and how to get it prescribed

Our cost guide puts the wellness peptides sold alongside glutathione (sermorelin, NAD+, PT-141) at roughly $150 to $350 a month, with in-clinic NAD+ infusions at $250 to $1,500 a session; glutathione sits at the cheap end because the ingredient costs little and clinician and pharmacy fees dominate. Price listings reviewed on October 9, 2026 put an intramuscular shot at a clinic at about $40 to $85, an IV session at about $75 to $300 (more for high doses or add-ons), and at-home compounded vials by telehealth at about $100 to $300 a month, typically around $180; the figures come from a provider-published guide and vary by city and dose (TrimRx 2026). A course of ten to twenty weekly IV sessions is a four-figure purchase for an outcome no trial has measured.

If you and a clinician decide to try glutathione anyway, the legitimate path looks like this:

1. A licensed clinician in your state reviews your history, asks about asthma, pregnancy and cancer, and documents why glutathione rather than the oral form or NAC.
2. The pharmacy is named and is a state-licensed 503A pharmacy (or an FDA-registered 503B facility), and it can tell you the grade and source of its glutathione and the lot on your vial.
3. The label carries a concentration and a beyond-use date, and the dose on it is the dose you use.
4. Nobody promises outcomes. A provider who guarantees lighter skin, 'detox' or energy is selling.

Glutathione for women and darker skin

The skin-lightening market is aimed overwhelmingly at women with darker skin tones, in the Philippines, South Asia, Africa and their diasporas, and the trials reflect it: Thai students, Filipino women, Indian clinic patients. The modest oral effect in those trials is real and temporary; the IV version marketed to the same women has no trial and two regulatory warnings behind it; and the dermatologists in those countries who see the results have been the loudest voices against IV glutathione, calling its unchecked use unjustified (Sonthalia 2018). There are no data in pregnancy or breastfeeding for any injected regimen, and the sensible position is to avoid it. See peptides for women for how glutathione compares with the compounds that do have data.

Bottom line

Glutathione is a real molecule with a real job inside cells, and the injections are a real prescription product that a US pharmacy may legally compound. What is missing is evidence that injecting it does what the menu says: the trials show modest, reversible skin lightening from capsules, a negative randomized trial of IV glutathione in Parkinson's disease and an uncontrolled oral pilot in fatty liver, nothing about detox, immunity or energy, and nothing at all about the 600 to 1,200 mg weekly IV regimens clinics sell. The safety record is good for the molecule in short trials and bad for the product in practice, with three endotoxin clusters in eight years and FDA warnings in 2019 and 2026.

A reasonable use is a short course prescribed by a clinician who can name the pharmacy, the ingredient grade and the lot, for a patient who has read this page and wants to try it anyway. An unreasonable use is a weekly drip bought on the promise of glow.

Frequently asked questions

+−Is glutathione a peptide?

Yes, technically. Glutathione is a tripeptide, three amino acids (glutamate, cysteine and glycine) joined together, made inside every cell in the body. It is sold alongside peptide therapies for that reason, but it is a different kind of molecule from the signaling peptides like BPC-157 or sermorelin: it is an antioxidant your cells already make in large amounts, and its job is to neutralize reactive molecules and help detoxify drugs and toxins inside cells.

+−What does glutathione do?

Inside cells it donates electrons to neutralize reactive oxygen species, keeps proteins in their working state, and is attached to toxins and drugs so the liver can excrete them. Those are facts about the glutathione your cells synthesize. Whether injecting extra glutathione into the bloodstream changes any of that in a healthy person is the open question, and the trials that have looked (Parkinson's disease, skin lightening) have been small and mostly negative.

+−Which is better for glutathione, an injection or an IV?

Neither has a trial for the uses they are sold for. An IV push or drip raises blood glutathione briefly; an intramuscular or subcutaneous shot does the same more slowly and in a smaller amount per session. Oral glutathione, the only form with randomized trials for skin lightening, raised body stores over months in one 6-month trial. The practical difference is risk: IV delivery of a contaminated product reaches the bloodstream fastest, which is how the 2018, 2019 and 2026 endotoxin cases happened.

+−What are the side effects of glutathione?

In short trials, few: oral and IV glutathione were well tolerated for days to weeks. The documented harms come from the products and the way they are used, not the molecule: fever, chills, low blood pressure and sepsis-like illness from endotoxin-contaminated compounded injections (seven cases in Sydney in 2018, seven US patients in 2019, about 30 in 2026); Stevens-Johnson syndrome, kidney and thyroid problems reported with IV whitening regimens in the Philippines; and bronchoconstriction in asthmatics with the nebulized form. Nobody has studied repeated weekly IV use for a year.

+−What is the best injection for whitening skin?

There is no injection with evidence for skin lightening. The only randomized trials are of oral glutathione (250 to 500 mg a day), which produced modest, reversible lightening in 4 to 12 weeks, and of topical glutathione. Intravenous glutathione has one unpublished-in-indexed-journals study that was negative, and a 2025 systematic review calls IV glutathione contraindicated for the purpose. The Philippine FDA has warned against it twice. If a clinic tells you the IV is the strong version, it is telling you the version without data.

+−Which type of glutathione is best for skin whitening?

In the trials, reduced glutathione (GSH) by mouth at 500 mg a day and both reduced and oxidized forms at 250 mg a day lowered the melanin index modestly; a 2 percent oxidized-glutathione lotion did the same on the applied side of the face. Liposomal and sublingual products claim better absorption but have not been compared head to head. None of them changes skin color permanently, and the effect faded after stopping in every study that checked.

+−Are glutathione injections legal? Can a doctor prescribe them?

Yes, in the United States a licensed clinician can prescribe glutathione and a state-licensed 503A compounding pharmacy can prepare it, because FDA lists it in Category 1 of its 503A nominations, which lets pharmacies compound it while FDA evaluates it; it is one of the few injectables sold at peptide clinics with a basis for compounding. It is not an FDA-approved drug, the pharmacy, not FDA, is responsible for its quality, and FDA has twice warned compounders not to make it from dietary-supplement-grade powder. Ask which pharmacy made it and what grade of ingredient it used.

+−What is the glutathione injection dosage?

There is no studied dose for the uses clinics sell. The marketed regimens are 600 to 1,200 mg intravenously one to three times a week, or 200 to 600 mg intramuscularly once or twice a week; the Philippine FDA's warnings describe those same 600 mg to 1.2 g weekly IV doses as unapproved and unsafe. The doses with trial data are oral: 250 to 500 mg a day for skin, 300 mg a day for fatty liver, 250 to 1,000 mg a day to raise body stores. The one randomized IV trial used 1,400 mg three times a week for four weeks in Parkinson's disease and found nothing.

+−Does glutathione give you energy?

No trial has measured energy or fatigue after glutathione injections. The energy claim is an inference from glutathione's role in cellular metabolism, and the closest data, a 6-month oral trial, measured blood glutathione levels and immune markers, not how people felt. If you feel better after an IV session, the fluid, the rest and the expectation are all candidates.

Sources

1. StudyArjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat 2012;23:97-102. (2012)
2. StudyWeschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol 2017;10:147-53. (2017)
3. ReviewSonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept 2018;8:15-21. (2018)
4. ReviewDavids LM, Van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: inadequate safety data. S Afr Med J 2016;106:782-6. (2016)
5. ReviewSarkar R, Yadav V, Yadav T, P J, Mandal I. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025;64:992-1004. (2025)
6. StudyHauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009;24:979-83. (2009)
7. StudySechi G et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1159-70. (1996)
8. StudyHonda Y et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol 2017;17:96. (2017)
9. StudyRichie JP Jr et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015;54:251-63. (2015)
10. StudyMarrades RM et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med 1997;156:425-30. (1997)
11. ReviewTraverso N et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913. (2013)
12. StudyJohnstone T et al. Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions. Epidemiol Infect 2018;146:931-4. (2018)
13. RegulatoryFDA. FDA warns compounders not to use glutathione from a specific supplier to compound sterile drugs (seven patients with adverse events after IV L-glutathione from one lot; endotoxin suspected). February 1, 2019. (2019)
14. RegulatoryFDA. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables. June 2019. (2019)
15. NewsPharma Now. FDA warns compounders about dietary-supplement-grade glutathione in injectables after about 30 adverse events (FDA communication of August 27, 2026; one supplier lot implicated; two Texas pharmacies recalled). August 28, 2026, updated September 21, 2026. (2026)
16. NewsRhoades A. CDC investigating illnesses tied to glutathione injections (more than 25 illnesses in four states; symptoms consistent with endotoxin; two Texas pharmacies recalled). Healio, September 17, 2026. (2026)
17. NewsDermatology Times. IV skin whitener could be deadly: Philippine FDA warns of Stevens-Johnson syndrome, toxic epidermal necrolysis, thyroid and kidney problems with intravenous glutathione used for whitening. May 18, 2011. (2011)
18. NewsMagsino D. FDA cites dangers of using injectable glutathione as skin lightener (Philippine FDA Advisory 2019-182: liver, kidney and nervous-system toxicity, Stevens-Johnson syndrome, theoretical skin-cancer risk; approved only as an adjunct to cisplatin chemotherapy). GMA News, July 8, 2019. (2019)
19. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (the three tests a bulk substance must pass, including a USP or NF monograph).
20. SourceTrimRx (telehealth provider blog). Glutathione cost in 2026: real pricing from telehealth to compounding (provider-published; prices as listed, June 2026). (2026)
21. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)